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ABSTRACT: Inhibition of histone demethylases has within
recent years advanced into a new strategy for treating cancer
and other diseases. Targeting speciﬁc histone demethylases can
be challenging, as the active sites of KDM1A-B and KDM4A-D
histone demethylases are highly conserved. Most inhibitors
developed up-to-date target either the cofactor- or substrate-
binding sites of these enzymes, resulting in a lack of selectivity
and oﬀ-target eﬀects. This study describes the discovery of the
ﬁrst peptide-based inhibitors of KDM4 histone demethylases
that do not share the histone peptide sequence or inhibit
through substrate competition. Through screening of DNA-
encoded peptide libraries against KDM1 and -4 histone
demethylases by phage display, two cyclic peptides targeting
the histone demethylase KDM4C were identiﬁed and developed as inhibitors by amino acid replacement, truncation, and
chemical modiﬁcations. Hydrogen/deuterium exchange mass spectrometry revealed that the peptide-based inhibitors target
KDM4C through substrate-independent interactions located on the surface remote from the active site within less conserved
regions of KDM4C. The sites discovered in this study provide a new approach of targeting KDM4C through substrate- and
cofactor-independent interactions and may be further explored to develop potent selective inhibitors and biological probes for
the KDM4 family.
The dynamic regulation of gene expression is controlled by a
range of mechanisms, among which reversible posttranslational
modiﬁcations (PTM) of the N-terminal tails of histone proteins
play an important role through aﬀecting chromatin structure.1,2
Deregulation of histone-modifying enzymes has been shown in a
number of diseases, including cancer;3 thus, inhibitors of histone-
modifying enzymes are interesting probes for investigating the
biological role of these enzymes and their potential as therapeutic
targets.
Until the discovery of the histone demethylase KDM1A in
2004, histone methylation was thought to be an irreversible
epigenetic mark.4 KDM1A and its paralog KDM1B are FAD-
dependent amino oxidases demethylating mono- and dimethy-
lated lysine 4 on histone H3 (H3K4me2/me1). The KDM4
family of Jumonji-domain containing demethylases was identi-
ﬁed in 20065 and consists of the six members KDM4A, -B, -C, -D,
-E, and −F. Among those, KDM4E and -F are considered
pseudo-genes,6,7 while KDM4A-D produce enzymatically active
gene products.8 KDM4 demethylases are known to demethylate
H3K9me2/3, H3K36me3/2, and H1.4K26me3/2 through a
hydroxylation reaction requiring the cofactors Fe(II) and 2-
oxoglutarate (2-OG).5,9 Due to their elevated activity and
expression in several forms of cancer, KDM1 and -4 proteins are
recognized as oncogenes.10,11 KDM1 is, among others,
associated with prostate, bladder, and estrogen-receptor-negative
breast cancer.12 The KDM4 family of histone demethylases has
repeatedly been shown to be involved in progression of hormone
dependent cancers, such as breast and prostate cancer through
coregulating hormone receptors.13−15 The development of
selective KDM1 or -4 inhibitors is impeded by the high structure
and sequence conservation of these enzymes; most known
inhibitors mimic either the FAD cofactor (KDM1) or 2-OG
through Fe(II)-binding (KDM4) and hence interact with a
plethora of other targets, such as 2-OG-dependent oxygenases
through iron chelation.16−19 The conjugation of iron chelating
compounds to the truncated histone peptide substrate has been
investigated as well,20,21 and it resulted in the discovery of the
ﬁrst KDM4 selective inhibitors. However, there is a need for
additional strategies to target histone demethylases through
noncofactor and nonsubstrate interactions. Novel inhibitory
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scaﬀolds targeting alternative sites on histone demethylases are
warranted, as they might hold the key to subfamily and isoform
selectivity.
Herein, we present the discovery of several peptide binders of
the histone demethylases KDM1A, -4A and -4C using phage
display, which are not related to the sequence of their natural
histone peptide substrates. Two of these peptides were
developed into inhibitors of KDM4C by amino acid replacement,
truncation, and chemical modiﬁcations. The inhibitors were
found to target KDM4C via substrate-independent interactions
on the surface of the enzyme located in neighboring regions of
the highly conserved active site and within less conserved
regions.
■ RESULTS AND DISCUSSION
Phage Display Screening. Phage display screening is a
versatile tool for the discovery of peptides binding to biological
targets such as proteins.22 A phage library displaying random
peptide sequences fused to the N-terminus of the phage protein
pIII was screened against the catalytic domains of histone
demethylases KDM1A, -1B, -4A, -4B, -4C, -4D, and -4E. The
library consisted of linear 7- and 12-mer peptide sequences (X7/
X12GGGS, X = random residues), and a cyclic peptide-phage
library with two cysteines bridging a random 7-mer peptide
sequence (ACX7CGGGS). After 4−5 rounds of biopanning
against the surface-immobilized target proteins, phages binding
to KDM1 and -4 proteins were ampliﬁed in E. coli, and phage-
ELISA revealed a number of potential KDM1 and -4 interacting
peptides (PP1−6, Table 1). Both cyclic and linear peptides were
identiﬁed, and the KDM1 and -4 binding phages did not share
any sequence motifs. The apparent aﬃnities of the phages were
established to be in the low μM range from competition
experiments performed between free and surface-immobilized
KDM protein for phage binding (Table 1 and Supporting
Information (SI) Figure S1). Cross aﬃnity testing of peptide-
phages PP1−6 against all KDM1 and -4 proteins revealed that
most phages were speciﬁc binders (SI Table S2); however, PP5
displayed some aﬃnity toward KDM1A, and PP3 showed weak
aﬃnity for several proteins.
After their identiﬁcation from phage display, the inhibitory
activity of the soluble peptides was assessed on their respective
epigenetic target proteins. The peptides were initially synthe-
sized including the phage-derived N- and C-terminal linker
sequences, and C-terminally amidated to resemble the fusion to
the phage protein pIII. The peptides were tested for demethylase
inhibitory activity against their targets KDM1A, KDM1B,
KDM4A, and KDM4C (SI Figures S2−6). The two cyclic
peptides 1 (derived from PP5) and 2 (derived from PP6)
inhibited KDM4C-mediated H3K9me3 demethylation with IC50
values of 1000 μM and 52 μM, respectively (Table 2).
Peptide Development. In order to increase the inhibitory
activity of 1 and 2 which was dramatically decreased in
comparison to the peptide-phages, their structures were
optimized. It was hypothesized that weak inhibition of 1 in
particular, but also 2, might originate from instability of the
peptides owing to the presence of aspartate and asparagine
residues that are known to destabilize peptides in solution,
leading to deamidation and isomerization.23 Hence, the aspartate
residues in peptide 1 were exchanged with alanine and/or
glutamate, and the asparagine residues in 2 were exchanged with
alanine. Single and double exchange of D6 and D7 to alanine in
peptide 1 gave analogues 3−5, and exchange to glutamate gave
6−8. The exchange of D6A (4) led to a dramatic increase in
inhibitory activity, and also the double substitution D6E/D7E
resulted in an increase in inhibitory potency. These ﬁndings
indicate that 1might indeed be inactive due to stability issues. All
other analogues of 1 were inactive. For 2, exchanges N6A and
N8A gave inactive peptides 9 and 10, whereas the double
exchange N6A/N8A yielded the 2-fold less active peptide 11.
The initial synthesis of peptides 1 and 2 included the phage-
derived linker sequences, an N-terminal alanine residue, and
three C-terminal glycine residues. To reduce the size of the
peptides, these nonrandomized sequences beyond the cysteines
were removed sequentially. First, peptide 4 was truncated from
either the N- or C-terminus, leading to inactive peptides 12 and
13. Truncation from both ends (14) reduced inhibitory activity
by only ∼10-fold. Truncation of 2 from the N- or both termini,
leading to peptides 15 and 17, resulted in loss of inhibitory
activity, while truncation from the C-terminus (16) reduced
inhibitory potency by ∼3-fold. Interestingly, also N-terminal
acetylation of 2 (24) led to a complete loss of inhibitory activity
on KDM4C, indicating that theN-terminal alanine residue serves
an important function in inhibiting KDM4C.
Disulﬁde bridges in peptides can sometimes be unfavorable
due to their tendency to undergo disulﬁde reshuﬄing in solution
with other cysteine containing compounds,24 such as the target
protein KDM4C. An alternative to disulﬁde bridge cyclization is
the coupling of cysteines using xylenes, which leads to a relatively
small increase of the disulﬁde bond length and stabilizes it.25 To
investigate the eﬀect of inserting xylenes into the disulﬁde bridge
of 2, the cysteines were linked by alkylation with o-, m- and p-α-
α′-dibromoxylenes to give 18, 19, and 20 (Figure 1).
Compounds 19 and 20 displayed comparable inhibitory activity
to 2, while 18 was inactive (SI Figure S7). m-Dibromoxylene
insertion was pursued further by modifying the truncated
peptides 16 and 14, leading to analogues 21 and 22, respectively.
While the potency of 21was increased∼30-fold compared to 16,
peptide 22 was inactive.
To investigate the functionally important amino acids of 21
and 14 in more detail, two alanine scans were performed. The
resulting 13 peptides were screened against KDM4C, and the
average decrease in inhibitory activity was compared to the
original peptides (Figure 2 and SI Figure S8). For 14, all alanine
analogues were less active than the original peptide (Figure 2A);
however, the exchanges W3A, G7A, and Y8A led to the most
profound decrease in activity, indicating that these residues form
a conformational binding epitope for interaction with KDM4C.
In case of 21, KDM4C inhibition decreased with substitutions
R5A, N6A, and M7A, suggesting a continuous linear binding
sequence (Figure 2B). Interestingly, substitution T4A (24) led to
Table 1. Peptide Sequences Targeting KDM1A, -B, and
KDM4A−C Identiﬁed from Phage Display, As Well As the
Apparent EC50 Values of the Peptide-Phages
protein phage-peptide sequence EC50 [μM]
KDM1A PP1 SHSEFWDWGPGGG 1.6
KDM1B PP2 AWDVIWDQLLQH 10
KDM4A PP3 GRMDWLGWRYELGGG 11
PP4 SHSMSNRAPSALVRIGGG 3.4
KDM4C PP5a ACKWMDDGYCGGG 56
PP6a ACYTRNMNQCGGG 1.3
aPeptides cyclized via disulﬁde bridge on the phage surface.
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improved inhibition (IC50 = 2.6 μM), indicating that the more
bulky threonine residue could hinder interaction with KDM4C.
Cellular Activity. The eﬀects of compounds 2, 4, and 21 on
cellular histone demethylation were investigated through cellular
Table 2. Amino Acid Sequences of Peptides 1 and 2 and Their Analogues, IC50 Values, and Hill Slopes on KDM4C
peptide sequence IC50 [μM]
a Hill slope
1 ACKWMDDGYCGGGb 1000
2 ACYTRNMNQCGGGb 52 ± 1.5 −0.42
3 ACKWMAAGYCGGGb >1000
4 ACKWMADGYCGGGb 8.5 ± 1.5 −0.56
5 ACKWMDAGYCGGGb >1000
6 ACKWMEEGYCGGGb ∼520
7 ACKWMDEGYCGGGb >1000
8 ACKWMEDGYCGGGb >1000
9 ACYTRAMNQCGGGb >1000
10 ACYTRNMAQCGGGb >1000
11 ACYTRAMAQCGGGb 97 ± 1.5 −0.90
12 CKWMADGYCGGGb >1000
13 ACKWMADGYCb >1000
14 CKWMADGYCb 76 ± 1.3 −0.93
15 CYTRNMNQCGGGb >1000
16 ACYTRNMNQCb 406 ± 1.3 −0.55
17 CYTRNMNQCb >1000
21 Meta-Xyl-ACYTRNMNQCc 16 ± 1.6 −0.70
22 Meta-Xyl-CKWMADGYCc >1000
23 ACYTRNMNQCGGGYGRKKRRQRRRb 0.6 ± 0.02 −0.46
24 Ac-ACYTRNMNCGGGb >1000
aDetermined by LANCEUltra KDM4C Histone H3K9 demethylase assay. Km (ccKDM4C) = 220 nM, c (H3K9me3) = 300 nM. Full dose−response
curves are shown in SI Figure S6. bPeptides cyclized by disulﬁde bridge. cPeptides cyclized by m-α-α′-dibromoxylene.
Figure 1. Compounds 18−22 cyclized by dibromoxylenes.
Figure 2. Average change in inhibitory activity of alanine analogues of peptide 14 (A) and 21 (B) on KDM4C normalized to the activity of the original
peptides. Error bars are standard deviation of the mean (n = 3).
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immunoﬂuorescence assays using osteosarcoma U2OS cells. In
addition, the eﬀect of attaching a cell penetrating TAT-peptide to
the C-terminus of peptide 2 was investigated (peptide 23).
Though an increase in inhibitory activity was observed for 23
(Table 2), no cellular activity on histone demethylase activity
could be detected for this or any of the other tested compounds
(data not shown). Most likely, the lack of activity was due to low
cell-permeability, cellular stability issues, and/or the insuﬃcient
inhibitory activity of the compounds.
Interaction with KDM4C. In order to investigate the
mechanism by which the peptides inhibit KDM4C in more
detail, the two best analogues from each series, 4 and 23, were
tested in substrate competition experiments. The Michaelis−
Menten kinetics of KDM4Cwere determined at various inhibitor
concentrations, as shown in Figure 3A, B. For both compounds,
the Km value initially decreased by∼30% upon inhibitor addition
but remained constant at higher inhibitor concentrations. In
contrast to this behavior, the Vmax values continuously decrease
with increasing inhibitor concentration. These results imply that
4 and 23 do not simply inhibit KDM4C in a substrate-
competitive manner, but through a type of noncompetitive
inhibition. Also, the shift of the intersection in the Lineweaver−
Burk plots to the right of the y-axis (Figure 3C, D) indicates an
atypical mechanism of inhibition, potentially through coopera-
tive binding with more than one peptide.
To dissect the mode of interaction between the inhibitors and
KDM4C, hydrogen−deuterium exchange (HDX) mass spec-
trometry (MS) was employed to explore the sites aﬀected by
peptide-binding on KDM4C in solution. HDX-MS monitors the
HDX of backbone amide hydrogens in a protein by MS;26 HDX
can be localized to diﬀerent regions of the protein by pepsin
proteolysis and mass analysis of the deuterium content of the
resulting peptic peptides. A ligand binding event can cause a
reduction in the deuterium uptake in regions of the protein
involved in binding. Prior to HDX, the peptides were incubated
with KDM4C for 30 min at room temperature (RT) to allow
Figure 3. Substrate-dependent inhibition of KDM4C by 4 (A, C) and 23 (B, D). (A, B) The velocity of KDM4C at diﬀerent inhibitor concentrations is
plotted against the substrate concentration, the tables show the respective Km and Vmax values. (C, D) Corresponding Lineweaver−Burk plots.
Figure 4. Diﬀerential HDX-MS data for KDM4C ± peptide inhibitors. (A) Histograms showing the percent reduction in HDX for KDM4C residues
113−120, 166−174, 205−215, 248−275, 331−344, and 347−356 by peptides 2, 21, 4, and 14. Values are calculated relative to the measured %D value
for free KDM4C (n = 3, error bars are standard deviation of the mean). B) HDX data for the four regions of interest are plotted over the structure of
KDM4C (pdb 2XML) with 113−120 highlighted in light blue, 166−174 in blue, 248−275 in orange, and 331−344 in light orange. The histone peptide
substrate is shown in red.
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binding of the peptide to the protein. Upon peptide addition,
reductions in deuterium uptake were observed on KDM4C
fragments 113−120 and 166−174 for peptides 2, 4, 14, and 21
(Figure 4A and SI Figure S12). Peptides 4 and 14 showed
additional alterations on 248−275, and 2, 4, and 14 on 331−344,
suggesting distinct binding modes. Inspection of the interacting
regions in the X-ray crystal structure of KDM4C indicates two
regions aﬀected by peptide binding; the ﬁrst one spanning
residues 113−120 (light blue) and 166−174 (blue) where all
inhibitory peptides induce reduced deuterium uptake for
KDM4C, and a second one covering 248−275 (orange) and
331−344 (light orange) on KDM4C (Figure 4B). All identiﬁed
regions are located on the surface of KDM4C and remote from
the substrate binding site (red). To verify that no interaction
takes place in the active site, regions involved in substrate binding
(205−215) and catalytic activity (347−356)27 were analyzed as
well, but no changes in HDX upon peptide addition could be
detected (Figure 4A). Thus, inhibition seems to occur through
interactions on the surface of KDM4C. The identiﬁed sites are
located within less conserved regions remote from the active site
of KDM4C, suggesting a potential selectivity toward inhibition of
distinct isoforms of the KDM4 family. These sites are also remote
from the N- and C-terminal tails of the construct and are most
likely accessible on the full-length enzyme, since the rest of the
protein sequence of the enzyme continues on the back side of the
view in Figure 4B. However, it remains to be established that the
compounds can inhibit full length enzymes. Considering that the
two surfaces (spanning from 113 to 120 and 166−174, and 248−
275 and 331−344) are too far apart to be reached by a single
peptide molecule, these results support the previously
hypothesized cooperative binding of the peptides to KDM4C.
Furthermore, the overall negative Hill slopes of the inhibitors
(Table 2) also indicate negative cooperative binding of the
inhibitors to KDM4C. Interestingly, it has been suggested in the
literature that the interactions between phage-display-derived
peptides and their target proteins are not only driven by the
monomeric sequence of the peptide but by its multimeric
presentation on the phage.28 The shown results could be
interpreted to support this suggestion.
Both the cross aﬃnity screening on phage-level (SI Table S2)
and the results from the HDX-MS analysis indicate that the
peptides could display a certain level of isoform selectivity. The
cross aﬃnity screening showed that PP5 (developed into 4) has
the highest aﬃnity on KDM4A, while PP6 (developed into 2 and
21) binds primarily to KDM4C. To test the peptides’ isoform
selectivity, 2, 4, and 21 were tested for their inhibitory activity on
KDM4A and -B by AlphaScreen, revealing that all three peptides
inhibit KDM4A and -B to various degrees, with 21 being the
most potent inhibitor, and 2 and 4 showing overall lower activity
(SI Figure S9). For all tested compounds, KDM4A shows the
highest level of inhibition, followed by KDM4C and then
KDM4B. These results are in good agreement with the degree of
structural conservation among KDM4A-C, which is highest
between KDM4A and -C. The IC50 values of 21 on KDM4A, -B,
and -C were determined in separate dose−response experiments
from AlphaScreen and ranged from 1.1 μM for KDM4B to 2.1
μM for KDM4A and 3.5 μM for KDM4C (SI Figure S10). These
results show that there is no selectivity of the compounds among
the KDM4 family. In principle, the compounds could also have
activity at other demethylases, but it is the aim of future studies to
establish a complete selectivity proﬁle.
Conclusion. In conclusion, phage display screening provided
a viable platform to identify inhibitors of histone demethylases.
Though the initial hits discovered by phage display showed only
moderate inhibitory behavior, it was possible to develop them
into more potent compounds through amino acid replacement,
truncation, and chemical modiﬁcations. The optimized KDM4C
inhibitors were analyzed biochemically with respect to their
target engagement, suggesting that inhibition takes place through
a mechanism that is not competitive and potentially involves
cooperative binding. This hypothesis was further supported by
the HDX-MS analysis that suggested two distinct binding
surfaces on the catalytic core of KDM4C located remote from the
active site. Initial optimization of the peptides increased the
potency of the inhibitors but did not lead to isoform selectivity.
However, since the sites aﬀected by peptide binding were found
to be located within a less conserved region of KDM4C, and the
phage display also suggested isoform selectivity, the peptide
sequences described may be developed into selective inhibitors
for individual KDM4 isoforms. It can further be speculated that
the peptides target protein−protein interactions, or dimerization
sites of KDM4C. Multiprotein complexes containing KDM4C
are believed to be important for the recruitment of the
demethylase to transcription sites; hence, the peptides could
potentially be used as tool compounds to abolish such
interactions. The dimerization of KDM4C has been demon-
strated in the literature;29 however, it remains unknown whether
the enzyme is functional as a mono- or as a dimer. Also, the
dimerization interface of KDM4C is unknown, albeit all KDM4
proteins normally crystallize as dimers. Though this dimerization
might be artiﬁcally induced through the high protein
concentrations required for crystal formation, the crystal
structure of KDM4C (pdb 2XML) indicates that the
dimerization surface is located between the N-terminal JmjN
domain and the β-hairpin (residues 112−135). If this site is
involved in dimer formation and dimerization is crucial for
demethylase activity, the binding of the peptides to this site, as
shown by HDX-MS, would disrupt the dimer and inhibit the
enzyme. Additional studies are, however, needed to verify this.
Based on our ﬁndings, we believe that the herein described
compounds are important new lead structures for developing
potent, selective tool compounds for both epigenetic therapy and
the study of the physiological role of KDM4C. Future studies will
aim at increasing potency through developing these interesting
scaﬀolds by further modiﬁcations and to further characterize the
biological activity of these peptides. Moreover, important goals
will be to induce isoform selectivity and cell-activity of the
peptides.
■ METHODS
Phage Display. Two linear 7-mer and 12-mer and a constrained
version of the peptide library were used for the selection. Microtiter
plates were coated at 4 °C for 16 h with 10 μM puriﬁed protein in 1×
PBS (20 mM sodium phosphate, 150 mM NaCl, pH 7.4, total volume
per well 100 μL). The microtiter plates were subsequently washed with
1× PBS and then blocked with 4% skim milk in 1× PBS for 1 h at RT.
Bacteriophages at around 1010−1011 pfu/ml were used for each panning
round. The constrained and linear libraries were mixed and panned
together in 1× PBS. After incubation for 1 h at RT, the plates were
washed 10 times with 1× PBS and bound peptide-phages were eluted
with glycine/HCl, pH = 2.2 for 10 min, followed by neutralization with
Tris-base, pH = 9.0. Eluted phages were used to infect exponentially
growing TG1 cells overnight at 37 °C. The following day, the peptide
phages were precipitated from the cell supernatant with phage
precipitation buﬀer (20% (w/v) PEG6000 in 2.5 M NaCl) and
redissolved in 300 μL 1× PBS. After 4−5 rounds of panning, single
clones were isolated and tested for KDM4A−E and KDM1A and -B
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binding in phage ELISA (procedure described in the Supporting
Information). Single stranded DNA was extracted from positive
clones,30 and the DNA was sequenced in the region corresponding to
the random peptide region.
More experimental details and the protocols for phage and peptide
ELISA are shown in the Supporting Information.
LANCE Ultra KDM4C Histone H3-Lysine 9 Demethylase
Assay. For inhibition studies on KDM4C, PerkinElmer’s LANCE
Ultra JMJD2C Histone H3-Lysine 9 demethylase assay was performed
according to the manufacturerś protocol. The catalytic core domain of
KDM4C (ccKDM4C) employed in the LANCE assay was prepared as
described previously.21 Assays were carried out in triplicate measure-
ments at RT; the total reaction volume was 10 μL/well. For inhibition
studies, 0.6 fmol ccKDM4C were incubated for 30 min with various
concentrations of the peptides prior to addition of the substrate mix,
containing 300 nM H3K9me3 peptide substrate. The reaction mixture
was allowed to incubate for another 30 min at RT, before the reaction
was stopped by addition of the detection mix. The TR-FRET signal was
read using a Saﬁre2TMmicroplate reader (Tecan). Reaction mixtures of
assay buﬀer without enzyme or without inhibitor were used as controls.
For curve ﬁtting and data analysis, GraphPad Prism 6.0 was used. All
experiments were performed at least in triplicate.
FDH-Coupled KDM4A Activity Assay. The FDH-coupled
KDM4A activity assay was performed according to a protocol described
by Leurs et al.31 Instead of 0.015mg ccKDM4C, an equimolar amount of
ccKDM4A was used.
AlphaScreen KDM4A, -B, and -C Demethylase Assay. All of the
enzymatic reactions were conducted in duplicate at RT for 60 min in a
10 μL mixture containing assay buﬀer, histone H3 peptide substrate,
demethylase enzyme, and the test compound. These 10 μL reactions
were carried out in wells of 384-well Optiplate (PerkinElmer). After
enzymatic reactions, 5 μL of anti-Mouse Acceptor beads (PerkinElmer,
diluted 1:250 with 1× detection buﬀer and 5 μL of primary antibody
(BPS, diluted 1:100 with 1× detection buﬀer) were added to the
reaction mix. After brief shaking, the plate was incubated for 30 min.
Finally, 10 μL of AlphaScreen Streptavidin-conjugated donor beads
(PerkinElmer, diluted 1:125 with 1× detection buﬀer) were added. In 15
min, the samples were measured in AlphaScreen microplate reader
(EnSpire Alpha 2390 Multilabel Reader, PerkinElmer). Enzyme activity
assays were performed in duplicates at each concentration. The
AlphaScreen intensity data were analyzed and compared. In the absence
of the compound, the intensity (Ce) in each data set was deﬁned as 100%
activity. In the absence of enzyme, the intensity (C0) in each data set was
deﬁned as 0% activity. The percent activity in the presence of each
compound was calculated according to the following equation: %
activity = (C − C0)/(Ce − C0), where C is the A-screen intensity in the
presence of the compound.
KDM1A and -B Demethylase Assay. For inhibition studies on
KDM1A and -B, a peroxidase-coupled assay monitoring hydrogen
peroxide production was performed as previously described.32 KDM1A
was purchased from BPSBioscience (Cat. No. 50097); KDM1B cloning,
expression, and puriﬁcation.33 The time courses of the reaction were
measured under aerobic conditions using a Beckman Instruments DU
series 600 spectrophotometer equipped with a thermostat-controlled
cell holder (T = 25 °C). The 100 μL reactions were initiated by addition
of enzyme (100−200 nM KDM1A, or 480 nM KDM1B) to reaction
mixtures consisting of 50 mM HEPES buﬀer (pH 7.5), 0.1 mM 4-
aminoantipyrine, 1 mM 3,5-dichloro-2-hydroxybenzene-sulfonic acid,
0.76 μMhorseradish peroxidase (Worthington Biochemical Corp.), 100
μM inhibitor, and 24 μM or 100 μM H3K4me2 for KDM1A and
KDM1B, respectively. Absorbance changes were monitored at 515 nm,
and an extinction coeﬃcient of 26 000 M−1 cm−1 was used to calculate
product formation. For curve ﬁtting and data analysis, GraphPad Prism
6.0 was used.
Cellular Immunoﬂuorescence Assay.U2OS cells were seeded 24
h before transfection. Transfection was performed with Fugene HD
transfection reagent as recommended by the manufacturer. Six hours
after transfection, the cells were harvested and seeded into multi-well
plates into media containing compound. Twenty hours after incubation
of cells with compounds, the cells were washed once in PBS, harvested
by ﬁxation with formaldehyde 4% aqueous solution, and washed 2 times
in PBS. Subsequently, the cells were permeabilised in PBS, 0.2% Triton
X-100 for 10 min at RT. Blocking was performed in PBS, 0.2% Triton X-
100, 5% FBS for 45 min at RT. The cells were incubated with primary
antibodies diluted 1 μg mL−1 in blocking solution overnight at 4 °C. The
primary antibodies used in the assays were HA.11 (Covance, MMS-
101P) and the antibodies detecting the marks are speciﬁed in SI Table
S3. After incubation with primary antibodies, the cells were washed 3
times with PBS, incubated with secondary antibodies diluted 1:1000
(Alexa ﬂuor 594 goat anti rabbit IgG, Invitrogen, A11012; Alexa ﬂour
488 donkey anti-mouse IgG, Invitrogen, A21202) and Hoechst, 20 μg
mL−1 (Sigma, 33342) in blocking solution, and washed again 3 times
with PBS. Finally, PBS was added and high throughput imaging and
analysis were performed by an IN Cell Analyzer 1000 (GE Healthcare).
In the analysis, individual cells were divided into HA+ (transfected cells)
and HA− (nontransfected cells). The IC50 values were based on an
average measure of the staining of the mark speciﬁed in SI Table S3 in
the transfected cells.
Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-
MS). The peptides were preincubated with ccKDM4C (expressed and
puriﬁed as for LANCE inhibition testing) for 30 min in order to allow
target binding equilibration prior to deuterium labeling. Continuous
amide H/D exchange was initiated by a 10-fold dilution of protiated
protein solutions in the presence or absence of peptide into the
corresponding deuterated buﬀer (12.5 mM HEPES pH 7.4, 5 μM
FeSO4, 100 μM ascorbate). Nondeuterated controls were prepared by
dilution into an identical protiated buﬀer. All HDX reactions were
carried out at RT and contained 1.2 μM ccKDM4C in the absence or
presence of 160 μMpeptide. At appropriate time points ranging from 15
s to 4 h, aliquots of the HDX reaction were quenched by addition of an
equal volume of ice-cold quenching buﬀer (300 mM phosphate (pH
2.3) and 50mMTCEP) resulting in a ﬁnal pH of 2.5. Quenched samples
were immediately frozen and stored at −80 °C. Samples were injected
into a cooled Waters nanoAcquity UPLC system for online pepsin
digestion and rapid desalting of the protein samples. After digestion of
the samples, the peptic peptides were trapped on a trap column (Waters
VanGuard C18, 1.7 μm, 2.1 × 5 mm) and desalted with 0.68% formic
acid in 8% acetonitrile, pH 2.3, 200 μL min−1 for 3 min. Peptides were
eluted from the trap to the analytical column (Waters XBridge C18, 1.7
μm, 1.0 × 100 mm) and separated with an 8−40% gradient of 0.68%
formic acid in acetonitrile (pH 2.3) over 12 min at a ﬂow rate of 40 μL/
min. Positive ion-electrospray ionization mass spectra of eluted peptides
were acquired on a Waters SynaptG2 HDMSmass spectrometer. Peptic
peptides were identiﬁed in separate experiments using collision-induced
dissociation tandem mass spectrometry performed with a data-
independent (MSE) acquisition scheme. A sequence coverage map of
peptic peptides of KDM4C identiﬁed from this analysis is shown in SI
Figure S11. The sequence coverage was 91.7% with a redundancy of
1.84. Mass spectra were processed using the MassLynx and DynamX
software packages (Waters Corp.). Complete deuteration of control
samples was achieved by incubation of 60 pmol KDM4C in the
deuterated buﬀer in the presence of 6 M guanidine for 24 h at 30 °C.
Average back exchange (i.e., deuterium loss) was measured as 37% for
the analyzed peptides. However, no corrections were made for this
deuterium loss as only the relative levels of deuterium incorporation of
all samples were compared. The HDX of KDM4C in the presence and
absence of peptide after 10 min exchange was measured in triplicate to
conﬁrm the signiﬁcance of the detected changes in deuterium uptake,
Signiﬁcant changes were deﬁned as 3× SD. HDX-MS analysis of
KDM4C was also performed in the presence of the nonbinding Peptide
1 and no signiﬁcant changes in HDX was observed in KDM4C due to
the presence of Peptide 1 (data not shown). For peptide 21, KDM4C
fragment 331−344 showed complex bimodal HDX kinetics that require
further investigation (data not shown). Protein structures were
visualized using PyMOL (DeLano Scientiﬁc).
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